Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine
Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine in Adults Aged 18 Years and Above: a Multicenter, Open-label, Partially Parallel-controlled Clinical Trial
Sponsor: Anhui Provincial Center for Disease Control and Prevention
This PHASE3 trial investigates COVID-19 and is currently completed. Anhui Provincial Center for Disease Control and Prevention leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE3
Status: Unknown → Completed
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2022 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE3
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anhui Provincial Center for Disease Control and Prevention
- Chongqing Center for Disease Control and Prevention
- Hunan Provincial Center for Disease Control and Prevention
- Jiangsu Province Centers for Disease Control and Prevention
- Shandong Province Centers for Disease Control and Prevention
- Yunnan Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .